Alimera Sciences Announces Issuance Of A Positive Appraisal Recommendation On ILUVIEN® For Consultation In The United Kingdom

Alimera Sciences Announces Issuance Of A Positive Appraisal Recommendation On
               ILUVIEN® For Consultation In The United Kingdom

  PR Newswire

  ATLANTA, June 14, 2013

-- Patient Access Scheme meets cost-effectiveness thresholds for subgroup of
DME patients

ATLANTA, June 14, 2013 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that the Appraisal Committee of the United Kingdom's National
Institute for Health and Care Excellence (NICE) has issued a positive
Appraisal Consultation Document (ACD) on ILUVIEN® for the treatment of
pseudophakic patients with chronic diabetic macular edema (DME) considered
insufficiently responsive to available therapies. The ACD recommends a change
to the published guidance issued by NICE on January 29, 2013, and takes into
consideration a simple patient access scheme (PAS) that was submitted by
Alimera for rapid review.

The NICE Appraisal Committee has reconfirmed ILUVIEN's clinical effectiveness
in the treatment of vision impairment associated with chronic DME considered
insufficiently responsive to available therapies. In the ACD, the Appraisal
Committee reiterated "that the technology had been shown to meet a clinical
need in people whose disease is unresponsive to available therapies."

Additionally, the committee noted that, based on the PAS, the
cost-effectiveness threshold has been met for a subgroup of chronic DME
patients who are pseudophakic, or have already undergone cataract replacement
surgery.

"I am delighted that the Appraisal Committee has reconsidered the NICE
guidance on ILUVIEN," said Mr. Winfried Amoaku, an associate professor and
consultant ophthalmologist with Nottingham University Hospitals NHS Trust.
"Chronic DME patients who are pseudophakic are now one step closer to
receiving this crucial sight-saving treatment from the National Health
Service. We cannot put a price on eyesight. Anything we can do to treat or
prevent vision loss is essential. I welcome the Appraisal Committee's
recommendation on the pseudophakic subgroup. It is hoped that NICE will update
its recommendation in the fullness of time to allow access for a wider
population of people with chronic DME."

"We are pleased with the Appraisal Committee's recommendation to provide
access to ILUVIEN for pseudophakic DME patients, which is an important step in
making this treatment available. We are optimistic that this ACD will lead to
a change in the final published guidance. We believe that ILUVIEN is also
effective in other groups of DME patients, and we plan to continue to work
with NICE to broaden access to ILUVIEN to include all chronic DME patients who
could benefit from the treatment," said Dan Myers, Alimera's president and
chief executive officer.

About ILUVIEN ^®

ILUVIEN (190 micrograms intravitreal implant in applicator) is a sustained
release intravitreal implant used to treat vision impairment associated with
chronic DME considered insufficiently responsive to available therapies. Each
ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering
sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is
injected in the back of the patient's eye to a position that takes advantage
of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle,
which allows for a self-sealing wound.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to
seven European countries via the Decentralized Procedure (DCP) with the
Medicines and Healthcare products Regulatory Agency of the United Kingdom
(MHRA) serving as the Reference Member State (RMS). The MAA included data from
two Phase 3 pivotal clinical trials (collectively known as the FAME™ Study)
for ILUVIEN conducted by Alimera. The trials involved 956 patients in sites
across the United States, Canada, Europe and India to assess the efficacy and
safety of ILUVIEN for the treatment of DME. At the end of the DCP, a consensus
was reached by the RMS and the other six countries that the MAA for ILUVIEN
was approvable. To date, six of the seven countries, Austria, the United
Kingdom, Portugal, France, Spain and Germany have granted national licenses
for ILUVIEN. ILUVIEN has not been approved by the United States Food and Drug
Administration.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a
non-proprietary corticosteroid with demonstrated efficacy in the treatment of
ocular disease.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning
of the Private Securities Litigation Reform Act of 1995, regarding, among
other things, the commercialization of ILUVIEN in the United Kingdom. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert
or change any of them, and could cause actual results to differ materially
from those projected in its forward-looking statements. Meaningful factors
which could cause actual results to differ include, but are not limited to
NICE's acceptance of the recommendations contained in ACD, uncertainty as to
Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the
United Kingdom, as well as other factors discussed in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" sections of Alimera's Annual Report on Form 10-K for the year
ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter
ended March 31, 2013, which are on file with the Securities and Exchange
Commission (SEC) and available on the SEC's website at www.sec.gov . In
addition to the risks described above and in Alimera's Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other
filings with the SEC, other unknown or unpredictable factors also could affect
Alimera's results. There can be no assurance that the actual results or
developments anticipated by Alimera will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects on,
Alimera. Therefore, no assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly
qualified by the cautionary statements contained or referred to herein.
Alimera cautions investors not to rely too heavily on the forward-looking
statements Alimera makes or that are made on its behalf. These forward-looking
statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such forward-looking
statements, whether as a result of new information, future events or
otherwise.

For press inquiries:
                                 For investor inquiries:
Katie Brazel, Fleishman-Hillard
                                 John Mills, ICR
for Alimera Sciences
                                 for Alimera Sciences +1-310-954-1105
+1-404-739-0150                 John.Mills@ICRINC.com

Katie.Brazel@fleishman.com





Website: http://www.alimerasciences.com